Minoxidil topical cream petition
This article was originally published in The Tan Sheet
Law firm Baker & Hostetler asks FDA to allow an abbreviated new drug application to change the topical dosage form for private-label Rogaine, according to a petition filed Dec. 11. The petition notes that changing the dosage for the hair regrowth product from a topical solution to a cream provides better application control and reduces the risk of skin irritation to non-affected areas. It requests the dosage change for the generic versions of Rogaine (For Women) 2 percent and Rogaine Extra Strength (For Men) 5 percent. The foam delivery form of Rogaine is patented through 2019 (1"The Tan Sheet" Sept. 11, 2006, p. 5)
You may also be interested in...
Pfizer Consumer Healthcare's new foam delivery form ofRogaine (minoxidil) carries three years of marketing exclusivity and is patent-protected through 2019, the firm announced Sept. 5
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.